SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. (NASDAQ: TCDA), a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-dosed polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease, today announced the closing of its initial public offering of 13,455,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase up to 1,755,000 shares of common stock for total gross proceeds of approximately $255.6 million, before deducting underwriting discounts and commissions and other offering expenses payable by Tricida. The shares began trading on The Nasdaq Global Select Market on June 28, 2018 under the symbol “TCDA.”
Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. The offering was made only by means of a prospectus, copies of which may be obtained from: Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing firstname.lastname@example.org; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 866-803-9204, or by emailing email@example.com; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 631-274-2806, or facsimile: 631-254-7140.
Registration statements relating to these securities has been filed with the U.S. Securities and Exchange Commission and became effective under the Securities Act of 1933, as amended, on June 27, 2018. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described above, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-dosed polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease.